Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Posoleucel (ALVR105)
Posoleucel · 1 trial · 6 indications
The number of participants experiencing clinically significant infections or episodes of end-organ disease due to AdV, BKV, CMV, EBV, HHV-6, or JCV through Week 14
| Arm | Type | Description |
|---|---|---|
| Posoleucel (ALVR105) | EXPERIMENTAL | Administered as 2-4 milliliter infusion |
| Name | Type | Description |
|---|---|---|
| Posoleucel (ALVR105) | BIOLOGICAL | Administered as 2-4 milliliter infusion |
Key Inclusion Criteria * ≥1 year of age at the day of screening visit. * Either no evidence of viral infection or viremia, or asymptomatic, viral infection with 3 or fewer viruses of interest at time of screening * Within 15 and 42 days of receiving a first allogeneic HCT and have demonstrated clin...
Posoleucel is an investigational cell therapy being studied for the prevention of adenovirus infection in patients who have received an allogeneic hematopoietic cell transplant. It has also been evaluated for prevention of several other viral infections in that same transplant setting, including BK virus, cytomegalovirus, Epstein-Barr virus, human herpes virus-6, and JC virus.
Posoleucel is being developed by Kalaris Therapeutics, Inc., which trades under the ticker KLRS. The company is the sponsor of the clinical program evaluating the therapy in transplant recipients.
Posoleucel is in Phase 2 development. It is an investigational cell therapy and is not approved for commercial use. The Phase 2 study evaluating it has been completed.
Posoleucel has been studied in the Phase 2 trial NCT04693637, titled Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant. The trial enrolled 26 patients in the United States and has been completed. It was an uncontrolled study without randomization or blinding.
Yes. Posoleucel is also known as ALVR105, and it was formerly called Viralym-M. These names refer to the same investigational cell therapy developed by Kalaris Therapeutics.